Commodore Capital LP Xenon Pharmaceuticals Inc. Transaction History

Commodore Capital LP

$1.12 Billion
Q2 2024

A detailed history of Commodore Capital LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Commodore Capital LP holds 2,754,266 shares of XENE stock, worth $112 Million. This represents 9.63% of its overall portfolio holdings.

Number of Shares

2,754,266

Previous 2,167,793 27.05%

Holding current value

$112 Million

Previous $93.3 Million 15.07%

% of portfolio

9.63%

Previous 8.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $21.3 Million - $25.7 Million	586,473 Added 27.05%	2,754,266 $107 Million
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $9.26 Million - $15 Million	322,793 Added 17.5%	2,167,793 $99.8 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $6.22 Million - $7.5 Million	185,889 Added 11.2%	1,845,000 $66 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $2.12 Million - $2.53 Million	64,179 Added 4.02%	1,659,111 $65.4 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $9.98 Million - $13.8 Million	392,319 Added 32.62%	1,594,932 $48.5 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $2.82 Million - $3.73 Million	112,487 Added 10.32%	1,202,613 $36.8 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $7.97 Million - $18.1 Million	510,694 Added 88.14%	1,090,126 $34.1 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $3.76 Million - $4.92 Million	253,096 Added 77.56%	579,432 $8.85 Million
Q2 2021 Aug 16, 2021	BUY	$16.81 - $20.0 $419,308 - $498,880	24,944 Added 8.28%	326,336 $6.08 Million
Q1 2021 May 17, 2021	SELL	$13.65 - $21.31 $2.27 Million - $3.54 Million	-165,976 Reduced 35.51%	301,392 $5.4 Million
Q4 2020 Feb 16, 2021	BUY	$9.49 - $16.04 $4.44 Million - $7.5 Million	467,368 New	467,368 $7.19 Million

Others Institutions Holding XENE

# of Institutions

221

Shares Held

69.6M

Call Options Held

59.7K

Put Options Held

60.7K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.54B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.

Account

Commodore Capital LP Xenon Pharmaceuticals Inc. Transaction History